Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Back-up arteriovenous fistula (bAVF) have been conventionally used in peritoneal dialysis (PD) to avoid transfer to haemodialysis with a central venous catheter (CVC). However, there is no clear evidence that a bAVF reduces meaningful clinical outcomes. All previous studies that examined the utility of a bAVF in PD patients were single centered and retrospective cohorts that limited the outcome to transfer to haemodialysis with a CVC or bAVF. Very few studies examined adverse events associated with creation of a bAVF. We therefore set out to compare bAVF versis no bAVF use, examining maturity of bAVF, vascular complications between the two groups and moretality as an outcome.
A Retrospective cohort study of adult patients in a Local Health District in Australia (2017- 2023) comparing patients with a bAVF to those with no bAVF. We included patients who commenced PD, or who transferred from haemodialysis with 3 months. Our primary outcome was mortality and secondary outcomes transfer to haemodialysis, transfer to haemodialysis with a CVC and vascular access complications (bAVF or CVC). We examined number of interventions, procedures and complications required in the bAVF group. Cox regression models were used to estimate hazard ratios (HR) and 95% condifence intervals (95%CI) between the groups. Poisson regression model was fitted to estimate incidence rate ratio (IRR) of the rate of CVC insertions between the two groups.
We included 115 patents in the analysis, 50 (44%) with a bAVF and 65 (56%) with no bAVF. In the 50 bAVF created 31 (62%) matured. 56 procedures were undertaken in the bAVF group (1.1 procedure/patient), which included 32 assisted intervention (0.6 assisted interventions/patient) . There was no difference in mortality between the bAVF group and no bAVF group (HR 0.8, 95%CI 0.4- 1.6, P= 0.6), transfer to haemodialysis (HR 1.0, 95%CI 0.5- 2.0, P= 0.9) or complications (HR 1.1, 95%CI 0.4- 3.0, P= 0.8). However, the presence of a bAVF significantly reduced the risk of haemodialysis transfer with a CVC (HR 0.4, 95%CI 0.1- 0.9, P= 0.04), while the the lack of a bAVF significantly increased the rate of CVC insertions (IRR 3.2, 95%CI 2.1- 4.8, P<0.001).
A bAVF was associated with a lower risk of transferring to haemodialysis with a CVC and reduced the rate of CVC insertions, when compared to those with no bAVF. However, there was no difference in mortality, risk of transferring to haemodialysis or in the complication rates. These risks and benefits need to be taken into account when going through the process of informed consent with patients. Additionally randomised controlled trials need to be implemented to determine the true utility of bAVF in PD populations.
